The use of Sirolimus for an unresectable and refractory venous malformation: A case series
Vascular malformations (VM) may become symptomatic and extensive, leading to deranged coagulation and bleeding. Sirolimus®, an antiangiogenic agent, has recently emerged as treatment for VM. We report its short-term outcomes for VMs of the extremities. Case 1: A 47-year-old female reported left fore...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Radiology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1930043325002262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850200963348955136 |
|---|---|
| author | Daniela Kristina Carolino, MD Keiichi Muramatsu, MD Yasuhiro Tani, MD Hideaki Sugimoto, MD Masaya Ueda, MD |
| author_facet | Daniela Kristina Carolino, MD Keiichi Muramatsu, MD Yasuhiro Tani, MD Hideaki Sugimoto, MD Masaya Ueda, MD |
| author_sort | Daniela Kristina Carolino, MD |
| collection | DOAJ |
| description | Vascular malformations (VM) may become symptomatic and extensive, leading to deranged coagulation and bleeding. Sirolimus®, an antiangiogenic agent, has recently emerged as treatment for VM. We report its short-term outcomes for VMs of the extremities. Case 1: A 47-year-old female reported left forearm pain. MRI confirmed a VM. Lesion shrinkage and pain relief were not achieved despite sclerotherapy. After 5 months on Sirolimus®, improved pain, decreased forearm circumference and decreased lesion size on MRI were observed. Case 2: 62-year-old male reported left knee pain. MRI and biopsy confirmed a VM. After 3 months on Sirolimus®, improved pain, decreased leg circumference, and decreased lesion size on MRI were observed. Our series demonstrates that Sirolimus® is efficacious in downsizing VMs with resultant symptom relief in the short-term. Other series has likewise shown effectivity in extensive and refractory lesions, with benefits outweighing side effects. |
| format | Article |
| id | doaj-art-2d4c213207594629bcd894b5eadbfd19 |
| institution | OA Journals |
| issn | 1930-0433 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Radiology Case Reports |
| spelling | doaj-art-2d4c213207594629bcd894b5eadbfd192025-08-20T02:12:09ZengElsevierRadiology Case Reports1930-04332025-06-012063081308510.1016/j.radcr.2025.03.016The use of Sirolimus for an unresectable and refractory venous malformation: A case seriesDaniela Kristina Carolino, MD0Keiichi Muramatsu, MD1Yasuhiro Tani, MD2Hideaki Sugimoto, MD3Masaya Ueda, MD4Department of Orthopedic Surgery, Nagato General Hospital, 85 Higashi-Fukawa, Yamaguchi 759-4194, Nagato, JapanCorresponding author.; Department of Orthopedic Surgery, Nagato General Hospital, 85 Higashi-Fukawa, Yamaguchi 759-4194, Nagato, JapanDepartment of Orthopedic Surgery, Nagato General Hospital, 85 Higashi-Fukawa, Yamaguchi 759-4194, Nagato, JapanDepartment of Orthopedic Surgery, Nagato General Hospital, 85 Higashi-Fukawa, Yamaguchi 759-4194, Nagato, JapanDepartment of Orthopedic Surgery, Nagato General Hospital, 85 Higashi-Fukawa, Yamaguchi 759-4194, Nagato, JapanVascular malformations (VM) may become symptomatic and extensive, leading to deranged coagulation and bleeding. Sirolimus®, an antiangiogenic agent, has recently emerged as treatment for VM. We report its short-term outcomes for VMs of the extremities. Case 1: A 47-year-old female reported left forearm pain. MRI confirmed a VM. Lesion shrinkage and pain relief were not achieved despite sclerotherapy. After 5 months on Sirolimus®, improved pain, decreased forearm circumference and decreased lesion size on MRI were observed. Case 2: 62-year-old male reported left knee pain. MRI and biopsy confirmed a VM. After 3 months on Sirolimus®, improved pain, decreased leg circumference, and decreased lesion size on MRI were observed. Our series demonstrates that Sirolimus® is efficacious in downsizing VMs with resultant symptom relief in the short-term. Other series has likewise shown effectivity in extensive and refractory lesions, with benefits outweighing side effects.http://www.sciencedirect.com/science/article/pii/S1930043325002262RapamycinSirolimusVenous malformationUnresectableExtremity |
| spellingShingle | Daniela Kristina Carolino, MD Keiichi Muramatsu, MD Yasuhiro Tani, MD Hideaki Sugimoto, MD Masaya Ueda, MD The use of Sirolimus for an unresectable and refractory venous malformation: A case series Radiology Case Reports Rapamycin Sirolimus Venous malformation Unresectable Extremity |
| title | The use of Sirolimus for an unresectable and refractory venous malformation: A case series |
| title_full | The use of Sirolimus for an unresectable and refractory venous malformation: A case series |
| title_fullStr | The use of Sirolimus for an unresectable and refractory venous malformation: A case series |
| title_full_unstemmed | The use of Sirolimus for an unresectable and refractory venous malformation: A case series |
| title_short | The use of Sirolimus for an unresectable and refractory venous malformation: A case series |
| title_sort | use of sirolimus for an unresectable and refractory venous malformation a case series |
| topic | Rapamycin Sirolimus Venous malformation Unresectable Extremity |
| url | http://www.sciencedirect.com/science/article/pii/S1930043325002262 |
| work_keys_str_mv | AT danielakristinacarolinomd theuseofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT keiichimuramatsumd theuseofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT yasuhirotanimd theuseofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT hideakisugimotomd theuseofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT masayauedamd theuseofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT danielakristinacarolinomd useofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT keiichimuramatsumd useofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT yasuhirotanimd useofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT hideakisugimotomd useofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries AT masayauedamd useofsirolimusforanunresectableandrefractoryvenousmalformationacaseseries |